Hyperphosphatemia in Chronic Kidney Disease On Dialysis

• FDA approval · 2025-03-21
  FDA Approved: XPHOZAH 10 MG — Supplemental Application (Ardelyx, Inc.)

  The FDA approved a supplemental application for XPHOZAH 10 mg (tenapanor) from Ardelyx, Inc., expanding the drug’s approved use or dosing.

• FDA approval · 2021-06-16
  FDA Approved: SEVELAMER HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals, Inc.)

  FDA approved Lupin Pharmaceuticals' generic sevelamer hydrochloride for the treatment of hyperphosphatemia in adults and pediatric patients …

• FDA approval · 2015-07-21
  FDA Approved: FERRIC CITRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)

  FDA approved a supplemental application for Ferric Citrate submitted by Mylan Pharmaceuticals, representing an additional regulatory action …